Nonsteroidal anti-inflammatory drug effectivity in preventing post-endoscopic retrograde cholangiopancreatography pancreatitis: A systematic review and meta-analysis

Table 1 Characteristics of the 26 randomized controlled trials, including administration route, dose, and type of non-steroidal anti-inflammatory drug

Ref.	Year	Country	Route	Dose	NSAID type
Andrade et al[24], 2015	2015	México	R	100 mg	Indomethacin
Bhatia et al[6], 2011	2011	India	IV	20 mg	Valdecoxib
Cheon et al[10], 2007	2007	United States	O	50 mg	Diclofenac
Döbrönte et al[7], 2014	2014	Hungary	R	100 mg	Indomethacin
Elmunzer et al[25], 2012	2012	United States	R	100 mg	Indomethacin
Hauser et al[11], 2016	2016	Croatia	R	100 mg	Diclofenac
Ishiwatari et al[12], 2016	2016	Japan	O	100 mg	Diclofenac
Kato et al[31], 2017	2017	Japan	O	400 mg	Celecoxib
Kato et al[13], 2019	2019	Japan	R	25/50 mg	Diclofenac
Khoshbaten et al[14], 2008	2008	Iran	R	50 mg	Diclofenac
Leerhøy et al[15], 2016	2016	Denmark	R	100 mg	Diclofenac
Levenick et al[26], 2016	2016	United States	R	100 mg	Indomethacin
Li et al[27], 2019	2019	China	R	100 mg	Indomethacin
Lua et al[16], 2015	2015	Malaysia	R	100 mg	Diclofenac
Mansour et al[32], 2016	2016	Iran	R	500 mg	Naproxen
Masjedizadeh et al[26], 2017	2017	Iran	R	50 mg	Indomethacin
Montaño et al[23], 2007	2007	México	R	100 mg	Indomethacin
Hosseini et al[28], 2016	2016	Iran	R	100 mg	Indomethacin
Murray et al[17], 2003	2003	Scotland	R	100 mg	Diclofenac
Otsuka et al[18], 2012	2012	Japan	R	50 mg	Diclofenac
Park et al[21], 2014	2014	South Korea	IM	100 mg	Diclofenac
Patai et al[29], 2015	2015	Hungary	R	100 mg	Indomethacin
Quadros et al[33], 2016	2016	Brazil	IV	100 mg	Ketoprofen
Senol et al[19], 2009	2009	United States	IV	50 mg	Diclofenac
Sotoudehmanesh et al[30], 2007	2007	Iran	R	100 mg	Indomethacin
Uçar et al[20], 2016	2016	Turkey	IM and IV	75/100 mg	Diclofenac

NSAIDs: Non-steroidal anti-inflammatory drugs; R: Rectal; IV: Intravenous; O: Oral; IM: Intramuscular.